Haisco(SZ:002653) Zheng Quan Shi Bao Wang·2026-01-06 08:05Core Viewpoint - The announcement indicates that the company has received a marketing authorization for its innovative drug HSK39297, which targets a significant unmet clinical need in the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1: Company Information - The company, Haikang Pharmaceutical, has a subsidiary named Sichuan Haikang Pharmaceutical Co., Ltd., which is responsible for the development of HSK39297 [1] - HSK39297 is positioned as a first-tier CFB inhibitor specifically for the treatment of PNH, highlighting its competitive edge in the market [1] Group 2: Market Potential - There is a substantial unmet clinical demand for treatments targeting PNH, suggesting a favorable market outlook for HSK39297 [1] - The drug's approval is expected to enhance the company's market presence in the therapeutic area of PNH, which is currently underserved [1]